<DOC>
	<DOCNO>NCT01163617</DOCNO>
	<brief_summary>This open-label , Phase 2 study design obtain user experience data ( Phase A ) injection time data ( Phase B ) experience adalimumab patient inject Physiolis pre-filled syringe autoinjector use administer adalimumab .</brief_summary>
	<brief_title>The Usability Injection Time Physiolis Syringe Autoinjector Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This Phase 2 , open-label study consist 2 study phase total 3 study visit , visit occur 2 week apart . Phase A ( User Experience ) randomize , 2-period , cross-over phase single subcutaneous ( SC ) dose injection administer use either Physiolis autoinjector current autoinjector Physiolis syringe current syringe 1:1 ratio . Phase B ( Injection Time ) randomize , single-visit , parallel-arm phase , injection test tube , one SC injection give participant use Physiolis autoinjector current autoinjector administer 2 different temperature range ( 2° 8°C [ storage temperature ] 20° 27°C [ room temperature ] ) . If participant complete Visit 1 Visit 2 , participant replace Visit 3 . If participant complete Visit 1 , participant replace study visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject judge good health determine investigator base upon result medical history , laboratory profile , physical examination , chest xray , 12lead electrocardiogram perform Screening . Subject negative purify protein derivative ( PPD ) test ( equivalent ) chest xray ( posterioranterior lateral view ) Screening . Subject diagnosis moderate severe rheumatoid arthritis treat adalimumab accordance FDAapproved Humira prescribe information . Subject must selfadministered adalimumab subcutaneous ( SC ) 40 mg injection every week ( eow ) without interruption least 3 month prior Screening . For Phase A portion study , subject must able willing self administer SC injection thigh abdomen ( administration another person permissible ) . Subject treated investigational drug chemical biologic nature within minimum 30 day 5 halflives ( whichever longer ) drug prior Visit 1 , exception adalimumab . Infection ( ) require treatment intravenous ( IV ) antiinfectives within 30 day prior Visit 1 oral antiinfectives within 14 day prior Visit 1 . Prior exposure natalizumab ( Tysabri® ) efalizumab ( Raptiva® ) . Known hypersensitivity adalimumab excipients . Regular use SC medication , exception adalimumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid</keyword>
	<keyword>Arthritis</keyword>
</DOC>